docetaxel anhydrous has been researched along with apatinib in 11 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (apatinib) | Trials (apatinib) | Recent Studies (post-2010) (apatinib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 575 | 109 | 544 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | apatinib (IC50) |
|---|---|---|---|
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, M; Kim, R; Mahipal, A | 1 |
| He, MF; Li, CY; Shen, LZ; Tan, AM; Wei, P; Wu, JQ; Zhai, J | 1 |
| Gao, G; Ren, S; Wu, F; Zhang, S; Zhao, J; Zhou, C | 1 |
| Aa, J; Feng, D; Feng, S; Gao, H; Gu, H; Peng, Y; Sun, R; Wang, G; Wang, Y; Yang, N; Zhang, J; Zhang, Y; Zhou, F | 1 |
| Aa, JY; Fei, F; Feng, SQ; Huang, JQ; Sun, RB; Wang, GJ; Wang, Y; Xie, Y; Zhang, JW; Zhou, F | 1 |
| Bai, H; Duan, JC; Hao, XZ; Hu, XS; Li, JL; Lin, L; Liu, YT; Wan, R; Wang, HY; Wang, J; Wang, X; Wang, Y; Wang, ZJ | 1 |
| Fang, XD; Hu, X; Jiang, Q; Ma, DY; Tan, BX; Zhang, NL | 1 |
| Gao, J; Liu, XL; Lu, HX; Yang, MD; Yang, WH | 1 |
| Chen, Z; Ge, L; Hu, R; Hui, K; Li, T; Wang, N; Wu, X; Zhou, L | 1 |
| Han, C; Li, H; Li, Z; Liu, Z; Sun, Z; Wu, Y; Zhang, J; Zhang, X | 1 |
| Fan, RY; He, MF; Huang, XE; Li, CY; Shen, LZ; Wang, P; Wei, P; Wu, JQ; Zhai, J | 1 |
3 review(s) available for docetaxel anhydrous and apatinib
| Article | Year |
|---|---|
Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Asian People; Camptothecin; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Pyridines; Ramucirumab; Stomach Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Neoplasm Staging; Pyridines; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyridines | 2021 |
2 trial(s) available for docetaxel anhydrous and apatinib
| Article | Year |
|---|---|
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2019 |
Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Preliminary Data; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Retreatment; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
6 other study(ies) available for docetaxel anhydrous and apatinib
| Article | Year |
|---|---|
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Humans; Male; Microinjections; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Pyridines; Stomach Neoplasms; Taxoids; Translational Research, Biomedical; Treatment Outcome; Zebrafish | 2017 |
Application of liquid chromatography-tandem mass spectrometry to study the effect of docetaxel on pharmacokinetics and tissue distribution of apatinib in mice.
Topics: Animals; Chromatography, Liquid; Docetaxel; Linear Models; Male; Mice; Mice, Inbred BALB C; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Taxoids; Tissue Distribution | 2018 |
Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Liver; Male; Mice, Nude; Protective Agents; Pyridines; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
[Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer].
Topics: Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Pyridines; Stomach Neoplasms | 2020 |
Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC.
Topics: A549 Cells; Aged; Autophagy; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Pyridines | 2020 |
Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Embryo, Nonmammalian; Fluorouracil; Humans; Proto-Oncogene Proteins c-akt; Pyridines; Ramucirumab; Stomach Neoplasms; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Zebrafish | 2022 |